Davis / Herbst / Abbruzzese | Antiangiogenic Cancer Therapy | Buch | 978-0-8493-2799-5 | www.sack.de

Buch, Englisch, 876 Seiten, Format (B × H): 178 mm x 254 mm, Gewicht: 1687 g

Davis / Herbst / Abbruzzese

Antiangiogenic Cancer Therapy


1. Auflage 2007
ISBN: 978-0-8493-2799-5
Verlag: Taylor & Francis

Buch, Englisch, 876 Seiten, Format (B × H): 178 mm x 254 mm, Gewicht: 1687 g

ISBN: 978-0-8493-2799-5
Verlag: Taylor & Francis


Top Investigators Explore the Complexities of Angiogenesis Cancer Research

The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bevacizumab, the first FDA approved angiogenesis inhibitor, with cytotoxic regimens has led to survival benefits in cancer patients. This has raised important questions about the complexities inherent in the clinical application of angiogenesis inhibitors.

Compiles the results of four decades of progress

Integrating fundamental concepts with therapeutic strategies, Anti-Angiogenic Cancer Therapy promotes the idea that an understanding of the molecular and cellular regulation of angiogenesis leads to optimal therapeutic strategies and positive clinical results. It brings together contributions from leading researchers to provide the most authoritative and encyclopedic volume available on this subject. - Examines the role of angiogenesis in cancer, including strategies to prolong the nonangiogenic dormant state of human tumors, molecular mechanisms and cellular regulation of angiogenesis in solid tumors and hematologic malignancies, and the regulation of angiogenesis by the tumor microenvironment.

- Covers specific molecular targets for inhibiting angiogenesis in cancer therapy.

- Discusses clinical trial design and translational research approaches essential for identifying and developing effective angiogenesis inhibitors.

- Outlines current understanding of the molecular biology of each cancer type followed by discussions that examine strategies for targeting angiogenesis in specific cancers.

This volume celebrates progress made in four decades, and more importantly, it provi

Davis / Herbst / Abbruzzese Antiangiogenic Cancer Therapy jetzt bestellen!

Zielgruppe


Professional Reference

Weitere Infos & Material


Angiogenesis in Cancer; Targeting Angiogenesis for Cancer Therapy; Translating Angiogenesis Inhibitors to the Clinic; Treatment of Specific Cancers with Angiogenesis Inhibitors


Darren W. Davis, Roy S. Herbst, James L. Abbruzzese



Ihre Fragen, Wünsche oder Anmerkungen
Vorname*
Nachname*
Ihre E-Mail-Adresse*
Kundennr.
Ihre Nachricht*
Lediglich mit * gekennzeichnete Felder sind Pflichtfelder.
Wenn Sie die im Kontaktformular eingegebenen Daten durch Klick auf den nachfolgenden Button übersenden, erklären Sie sich damit einverstanden, dass wir Ihr Angaben für die Beantwortung Ihrer Anfrage verwenden. Selbstverständlich werden Ihre Daten vertraulich behandelt und nicht an Dritte weitergegeben. Sie können der Verwendung Ihrer Daten jederzeit widersprechen. Das Datenhandling bei Sack Fachmedien erklären wir Ihnen in unserer Datenschutzerklärung.